The usage of selective estrogen receptor modulators (SERMs) and antioxidants, whose effectiveness has been thoroughly evaluated in both preclinical and clinical models of CRPC, has paved the way for cutting-edge therapeutic approaches for the treatment of PCa [11,12]. This evidence concerns the gene ESR1 and posterior cortical atrophy.